Is the CSL (ASX:CSL) share price on the road to recovery?

The CSL Limited (ASX: CSL) share price has rebounded strongly since hitting a 52-week low of $242.00 in early March. The company is pushing forward with its locally manufactured COVID-19 vaccine rollout and implementing initiatives to restore plasma collections levels.

By yesterday’s market close, the global biotech’s shares finished the day 1.4% higher at $269.83.

With the latest developments, is the CSL share price finally on the road to recovery? Let’s take a look at what’s been happening for the biotech giant.

Vaccine update

Investors have buying CSL shares ahead of renewed optimism that the worst is behind the company.

According to the Australian Therapeutic Goods Administration (TGA), the first four batches of…